Active Studies

RATIONALE: Lenalidomide and bortezomib may stop the growth of multiple myeloma by blocking
blood flow to the tumor. Also, bortezomib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Monoclonal antibodies, such as elotuzumab, can
block cancer growth in different ways. Some block the ability of cancer cells to grow and
spread. Others find cancer cells and help kill them or carry cancer-killing substances to
them. Drugs used in chemotherapy, such as lenalidomide and dexamethasone also work in
different ways to kill tumor cells or stop them from growing. Giving elotuzumab together
with chemotherapy may be a better way to block cancer growth.

PURPOSE: This phase I/II trial is studying the side effects and best dose of elotuzumab and
to see how well it works when given with lenalidomide, bortezomib, and dexamethasone in
treating patients with multiple myeloma.

The purpose of this study is to understand cognitive impairment in end stage renal disease before and after a kidney transplant.

Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.